See the DrugPatentWatch profile for Afrezza
What clinical trials have been done for Afrezza (insulin human inhalation)?
Afrezza is an inhaled form of insulin. The core evidence for Afrezza in clinical trials has focused on two things: blood-sugar control in people with diabetes and comparisons against injectable mealtime insulin regimens.
What do Afrezza trials measure (and how do researchers compare results)?
Trials typically evaluate how well Afrezza controls post-meal glucose (often using measures that reflect “time-matched” insulin exposure after dosing) and how it affects overall longer-term control in diabetes populations. Study designs commonly compare inhaled insulin given before meals versus standard injectable insulin strategies, tracking changes in glycemic endpoints over the study period.
Are there trials in type 1 diabetes and type 2 diabetes?
Yes. Afrezza’s clinical development includes studies across diabetes types, with inhaled insulin tested for use around meals and assessed for effects on both short-term glucose after eating and longer-term glycemic markers.
What are the main safety issues that clinical trials track for Afrezza?
Across inhaled insulin programs, safety monitoring centers on respiratory effects because the drug is delivered to the lungs. Afrezza clinical trials track lung-related adverse events and overall tolerability, alongside the expected insulin-related risks such as hypoglycemia. Trial inclusion criteria often account for baseline lung function because inhaled therapies can change risk profiles.
How do patients typically ask about clinical-trial dosing and timing?
A common trial question for inhaled mealtime insulins is whether the insulin is taken right before meals and how closely the dosing needs to match food intake. Clinical studies generally standardize timing (e.g., dosing immediately before eating) to test whether inhaled insulin can cover post-meal glucose excursions effectively.
Where can I find trial details and references?
For drug-by-drug trial and patent/exclusivity research, DrugPatentWatch.com can be a useful starting point when you want to locate clinical-development information tied to specific products. You can search Afrezza there here: DrugPatentWatch.com – Afrezza.
What to look for if you’re reviewing Afrezza trial reports
When comparing or interpreting Afrezza trial results, focus on:
- Study population (type 1 vs type 2, baseline A1c, insulin use history)
- Meal-time dosing rules (how timing was standardized)
- Respiratory endpoints and lung-function criteria
- Hypoglycemia rates and severity categories
- Duration of follow-up (short-term post-meal effects vs longer-term control)
If you share which Afrezza clinical trial you mean (for example, a specific NCT number, a publication title, or whether you’re looking at type 1 vs type 2), I can narrow the answer to that exact study’s design, endpoints, and outcomes.
Sources
- DrugPatentWatch.com – Afrezza